The Rush to Comparative Effectiveness: FDA's Woodcock Hopes It Won't Overshadow Personalized Medicine
This article was originally published in RPM Report
Executive Summary
Comparative effectiveness research is a central theme of the Obama Administration's health reform effort. But as the debate heats up on Capitol Hill, one top FDA official, Janet Woodcock, doesn't want to lose sight of an increasingly important drug development strategy: personalized medicine.
You may also be interested in...
FDA and Health Care Reform: An Activist Agenda for the Agency
Everyone is gearing up for a debate over health care reform in 2009-including the Food & Drug Administration. The regulator's role may be bigger than you think.
Comparative Effectiveness: Knowledge Not Coverage
The health industry's trade association supports a more formal and expanded federal comparative effectiveness research effort, with one caveat: the effort must be devoted to collecting and disseminating informaiton and not be tied directly to coverae or payment decisions. That aligns the health plans with Senate Finance Committee Chairman Max Baucus and creates a potent base for getting comparative effectiveness into upcoming health reform efforts.
The Next Steps for Personalized Health Care: Incentivizing Product Development
Roche has positioned itself as a leader in the development of more "personalized" health care products. What's needed now, CEO Abercrombie says, is a commitment from FDA to develop consistent approval standards and from CMS to guarantee coverage.